Pages that link to "Q51943531"
Jump to navigation
Jump to search
The following pages link to Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer (Q51943531):
Displaying 50 items.
- Interactome of the negative regulator of nuclear import BRCA1-binding protein 2 (Q24329017) (← links)
- CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer (Q28473504) (← links)
- Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy (Q30434260) (← links)
- Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. (Q30477571) (← links)
- Phosphosignature predicts dasatinib response in non-small cell lung cancer. (Q30524724) (← links)
- HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination (Q33275622) (← links)
- Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer (Q33813431) (← links)
- RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. (Q34048144) (← links)
- In silico models of cancer (Q34137584) (← links)
- Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis (Q34416157) (← links)
- Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer (Q34440998) (← links)
- Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial (Q34714877) (← links)
- Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer (Q34994030) (← links)
- Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy (Q35075617) (← links)
- Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction (Q35558070) (← links)
- High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? (Q35605840) (← links)
- Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes (Q35856517) (← links)
- Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients (Q36117673) (← links)
- MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. (Q36157026) (← links)
- Breast cancer expression profiling: the impact of microarray testing on clinical decision making (Q36613933) (← links)
- Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression (Q36924856) (← links)
- Limitations of pharmacogenomic predictor discovery in Phase II clinical trials (Q36989854) (← links)
- Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient (Q37347521) (← links)
- Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. (Q37401557) (← links)
- In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. (Q37423763) (← links)
- Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. (Q37444430) (← links)
- Blood-based transcriptomics: leukemias and beyond (Q37451562) (← links)
- Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook (Q37513837) (← links)
- Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis (Q37555371) (← links)
- Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases (Q37582863) (← links)
- A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy (Q37662215) (← links)
- Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers (Q37693959) (← links)
- Molecular basis for therapy resistance (Q37751530) (← links)
- Primary systemic chemotherapy of breast cancer: indication and predictive factors (Q37801866) (← links)
- Transcriptional profile and response to neoadjuvante chemotherapy in breast cancer (Q37892406) (← links)
- Gene expression profiling in breast cancer: classification, prognostication, and prediction (Q37958156) (← links)
- Genomic approach towards personalized anticancer drug therapy (Q37976828) (← links)
- An update on chemotherapy and tumor gene expression profiles in breast cancer (Q38017302) (← links)
- Molecular tests as prognostic factors in breast cancer (Q38184381) (← links)
- Histopathological assessment of tumour regression, nodal stage and status of resection margins determines prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy (Q39405849) (← links)
- Probenecid is a chemosensitizer in cancer cell lines (Q39485986) (← links)
- Proteomic approaches for investigation of therapy resistance in cancer (Q39959305) (← links)
- Etiology-dependent molecular mechanisms in human hepatocarcinogenesis (Q40030460) (← links)
- Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer (Q40646057) (← links)
- Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer (Q41134662) (← links)
- A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score (Q41179097) (← links)
- Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer (Q42677510) (← links)
- Identification of unique and common low abundance tumour-specific transcripts by suppression subtractive hybridization and oligonucleotide probe array analysis. (Q43775179) (← links)
- Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer (Q44283854) (← links)
- Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer (Q44700598) (← links)